Conflict of interest
This article was originally published in The Tan Sheet
NEJM revises conflict of interest policies for review articles, editorials that do not contain new data. New policy substitutes phrase "authors...will not have any financial interest in a company (or its competitor) that makes a product discussed in the article" with "not have any significant financial interest." Addition of word significant "acknowledges that not all financial associations are the same," editors write in June 13 issue. Significant means a $10,000 annual financial interest, the same de minimis level as that set by NIH, Association of American Medical Colleges. Journal's policy on research grants continues to require that authors cannot have major research support, funding from relevant companies...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”